Table 1. Recent University of California, San Francisco pharma deals.

Date

Company

Disease area

Project description

Funding

January 2011

sanofi-aventis Group (Euronext:SAN; NYSE:SNY)

Various

Funds discovery stage and preclinical work through UCSF's Program in Breakthrough Biomedical Research, an investigator-initiated grant program.

Up to 5 grants of up to $0.5M per year

January 2011

sanofi-aventis

Cancer

Project-based collaboration advances selected compounds and targets into clinical proof of concept.

Undisclosed

January 2011

Bayer AG
(Xetra:BAY)

Various

Establishes a research agreement to accelerate collaboration with UCSF researchers; Bayer to open a translational science center at UCSF's Mission Bay campus.

Undetermined

November 2010

Pfizer Inc.
(NYSE:PFE)

Various

Creates a translational research center at UCSF's Mission Bay campus; provides research funding and access to Pfizer's compound and antibody libraries.

Up to $85M in research support and milestones

June 2010

Merck & Co. Inc. (NYSE:MRK)

Cancer

Selects UCSF as one of 15 worldwide Merck Oncology Collaborative Trials Network sites; Merck provides funding for clinical trial infrastructure and access to compounds for investigator-initiated trials.

Undisclosed

February 2010

Genentech Inc./Roche
(SIX:ROG; OTCQX:RHHBY)

Neurodegenerative disease

Funds small molecule discovery efforts at UCSF's Institute for Quantitative Biosciences.

>$13M in milestones plus royalties

June 2009

Abbott Laboratories (NYSE:ABT)

Infectious disease

Funds a microarray diagnostics and virus discovery center at UCSF's Mission Bay campus.

Undisclosed